LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...

The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...

Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large ...

Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...

T he new weight-loss drugs Wegovy and Zepbound are in high demand, and the clamoring will only increase in coming years, ...

Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...

A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...